Bristol-Myers Squibb Company (BMY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bristol-Myers Squibb Company (BMY) has a cash flow conversion efficiency ratio of 0.152x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.39 Billion) by net assets ($22.32 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Bristol-Myers Squibb Company market capitalisation for the company's overall valuation and market capitalisation.
Bristol-Myers Squibb Company - Cash Flow Conversion Efficiency Trend (1989–2025)
This chart illustrates how Bristol-Myers Squibb Company's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Bristol-Myers Squibb Company Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bristol-Myers Squibb Company ranked by their cash flow conversion efficiency. Explore Bristol-Myers Squibb Company cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
0.056x |
|
Corning Incorporated
NYSE:GLW
|
0.029x |
|
Newmont Goldcorp Corp
NYSE:NEM
|
0.083x |
|
Mizuho Financial Group Inc.
NYSE:MFG
|
0.051x |
|
Prologis Inc
NYSE:PLD
|
0.023x |
|
Rio Tinto Group
MX:RION
|
0.042x |
|
ABB Ltd
SW:ABBN
|
0.117x |
|
SCHNEIDER ELECTR.ADR/1/5
F:SNDB
|
N/A |
Annual Cash Flow Conversion Efficiency for Bristol-Myers Squibb Company (1989–2025)
The table below shows the annual cash flow conversion efficiency of Bristol-Myers Squibb Company from 1989 to 2025. View Bristol-Myers Squibb Company (BMY) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $18.51 Billion | $14.16 Billion | 0.765x | -17.47% |
| 2024-12-31 | $16.39 Billion | $15.19 Billion | 0.927x | +97.18% |
| 2023-12-31 | $29.48 Billion | $13.86 Billion | 0.470x | +11.95% |
| 2022-12-31 | $31.12 Billion | $13.07 Billion | 0.420x | -6.72% |
| 2021-12-31 | $36.01 Billion | $16.21 Billion | 0.450x | +21.35% |
| 2020-12-31 | $37.88 Billion | $14.05 Billion | 0.371x | +137.72% |
| 2019-12-31 | $51.70 Billion | $8.07 Billion | 0.156x | -68.80% |
| 2018-12-31 | $14.13 Billion | $7.07 Billion | 0.500x | +12.33% |
| 2017-12-31 | $11.85 Billion | $5.28 Billion | 0.445x | +138.02% |
| 2016-12-31 | $16.35 Billion | $3.06 Billion | 0.187x | +28.18% |
| 2015-12-31 | $14.42 Billion | $2.10 Billion | 0.146x | -30.54% |
| 2014-12-31 | $14.98 Billion | $3.15 Billion | 0.210x | -9.70% |
| 2013-12-31 | $15.24 Billion | $3.54 Billion | 0.233x | -54.28% |
| 2012-12-31 | $13.64 Billion | $6.94 Billion | 0.509x | +66.85% |
| 2011-12-31 | $15.87 Billion | $4.84 Billion | 0.305x | +6.22% |
| 2010-12-31 | $15.64 Billion | $4.49 Billion | 0.287x | +4.45% |
| 2009-12-31 | $14.79 Billion | $4.07 Billion | 0.275x | -9.46% |
| 2008-12-31 | $12.21 Billion | $3.71 Billion | 0.304x | +1.72% |
| 2007-12-31 | $10.56 Billion | $3.15 Billion | 0.299x | +43.18% |
| 2006-12-31 | $9.99 Billion | $2.08 Billion | 0.208x | +27.27% |
| 2005-12-31 | $11.21 Billion | $1.84 Billion | 0.164x | -47.38% |
| 2004-12-31 | $10.20 Billion | $3.18 Billion | 0.311x | -13.25% |
| 2003-12-31 | $9.79 Billion | $3.51 Billion | 0.359x | +232.52% |
| 2002-12-31 | $8.76 Billion | $945.00 Million | 0.108x | -78.55% |
| 2001-12-31 | $10.74 Billion | $5.40 Billion | 0.503x | -0.71% |
| 2000-12-31 | $9.18 Billion | $4.65 Billion | 0.507x | +3.71% |
| 1999-12-31 | $8.64 Billion | $4.22 Billion | 0.489x | -2.12% |
| 1998-12-31 | $7.58 Billion | $3.78 Billion | 0.499x | +45.55% |
| 1997-12-31 | $7.22 Billion | $2.48 Billion | 0.343x | -14.68% |
| 1996-12-31 | $6.57 Billion | $2.64 Billion | 0.402x | -6.35% |
| 1995-12-31 | $5.82 Billion | $2.50 Billion | 0.429x | +6.40% |
| 1994-12-31 | $5.70 Billion | $2.30 Billion | 0.403x | -7.12% |
| 1993-12-31 | $5.94 Billion | $2.58 Billion | 0.434x | +28.93% |
| 1992-12-31 | $6.02 Billion | $2.03 Billion | 0.337x | +6.39% |
| 1991-12-31 | $5.79 Billion | $1.83 Billion | 0.317x | -2.08% |
| 1990-12-31 | $5.42 Billion | $1.75 Billion | 0.323x | +38.15% |
| 1989-12-31 | $5.08 Billion | $1.19 Billion | 0.234x | -- |
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rhe… Read more